The final Cox regression model
| . | HR (95% CI) . | P . | Score . |
|---|---|---|---|
| Age, y | |||
| ≤75 | 1 | — | 0 |
| 76-80 | 1.13 (0.76-1.69) | .549 | 1 |
| >80 | 2.40 (1.56-3.71) | <.001 | 2 |
| ADL | |||
| >4 | 1 | — | 0 |
| ≤4 | 1.67 (1.08-2.56) | .020 | 1 |
| IADL | |||
| >5 | 1 | — | 0 |
| ≤5 | 1.43 (0.96-2.14) | .078 | 1 |
| CCI | |||
| ≤1 | 1 | — | 0 |
| ≥2 | 1.37 (0.92-2.05) | .125 | 1 |
| ISS | |||
| I | 1 | — | — |
| II | 2.37 (1.38-4.09) | .002 | — |
| III | 3.21 (1.85-5.58) | <.001 | — |
| Chromosome abnormalities | |||
| Favorable | 1 | — | — |
| Unfavorable | 1.79 (1.23-2.60) | .002 | — |
| Missing | 1.13 (0.69-1.83) | .036 | — |
| Therapy | |||
| Proteasome inhibitors | 1 | — | — |
| Lenalidomide | 0.74 (0.50-1.11) | .142 | — |
| . | HR (95% CI) . | P . | Score . |
|---|---|---|---|
| Age, y | |||
| ≤75 | 1 | — | 0 |
| 76-80 | 1.13 (0.76-1.69) | .549 | 1 |
| >80 | 2.40 (1.56-3.71) | <.001 | 2 |
| ADL | |||
| >4 | 1 | — | 0 |
| ≤4 | 1.67 (1.08-2.56) | .020 | 1 |
| IADL | |||
| >5 | 1 | — | 0 |
| ≤5 | 1.43 (0.96-2.14) | .078 | 1 |
| CCI | |||
| ≤1 | 1 | — | 0 |
| ≥2 | 1.37 (0.92-2.05) | .125 | 1 |
| ISS | |||
| I | 1 | — | — |
| II | 2.37 (1.38-4.09) | .002 | — |
| III | 3.21 (1.85-5.58) | <.001 | — |
| Chromosome abnormalities | |||
| Favorable | 1 | — | — |
| Unfavorable | 1.79 (1.23-2.60) | .002 | — |
| Missing | 1.13 (0.69-1.83) | .036 | — |
| Therapy | |||
| Proteasome inhibitors | 1 | — | — |
| Lenalidomide | 0.74 (0.50-1.11) | .142 | — |
HRs and relative risks are for OS in patients with the factors as compared with those without the factors. The model was adjusted for ISS, chromosome abnormalities, and therapy. Unfavorable profile defined as t(4;14) or t(14;16) or del17p13.
AIC = 1748.918; Harrell C index = 0.7069.